|
JP2005289809A
(ja)
|
2001-10-24 |
2005-10-20 |
Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) |
突然変異重鎖抗体
|
|
AU2006249144B2
(en)
|
2005-05-18 |
2011-11-17 |
Ablynx Nv |
Improved NanobodiesTM against Tumor Necrosis Factor-alpha
|
|
DE102005023617A1
(de)
|
2005-05-21 |
2006-11-23 |
Aspre Ag |
Verfahren zum Mischen von Farben in einem Display
|
|
US9023352B2
(en)
|
2007-02-20 |
2015-05-05 |
Tufts University |
Methods, compositions and kits for treating a subject using a recombinant heteromultimeric neutralizing binding protein
|
|
CN103396489A
(zh)
|
2007-02-23 |
2013-11-20 |
默沙东公司 |
工程改造的抗IL-23p19抗体
|
|
HUE042172T2
(hu)
|
2007-02-23 |
2019-06-28 |
Merck Sharp & Dohme |
Genetikailag elõállított anti-il-23P19 antitestek
|
|
EP2535350B1
(en)
|
2007-09-26 |
2018-01-24 |
UCB Biopharma SPRL |
Dual specificity antibody fusions
|
|
CA2706425A1
(en)
*
|
2007-11-27 |
2009-06-04 |
Ablynx N.V. |
Method for obtaining polypeptide constructs comprising two or more single domain antibodies
|
|
US8444976B2
(en)
|
2008-07-02 |
2013-05-21 |
Argen-X B.V. |
Antigen binding polypeptides
|
|
US10407513B2
(en)
|
2008-09-26 |
2019-09-10 |
Ucb Biopharma Sprl |
Biological products
|
|
CN105646643A
(zh)
|
2008-10-29 |
2016-06-08 |
阿布林克斯公司 |
单域抗原结合性分子的纯化方法
|
|
RU2481824C2
(ru)
|
2008-10-29 |
2013-05-20 |
Аблинкс Н.В |
Препараты однодоменных антигенсвязывающих молекул
|
|
CA2746395C
(en)
*
|
2008-12-10 |
2019-07-09 |
Ablynx N.V. |
Polypeptides comprising amino acid sequences directed against tie 2 for the treatment of diseases and disorders related to angiogenesis
|
|
CA2747644C
(en)
|
2008-12-19 |
2023-01-24 |
Ablynx N.V. |
Method for generation of immunoglobulin sequences
|
|
EP2403873A1
(en)
|
2009-03-05 |
2012-01-11 |
Ablynx N.V. |
Novel antigen binding dimer-complexes, methods of making/avoiding and uses thereof
|
|
US9265834B2
(en)
|
2009-03-05 |
2016-02-23 |
Ablynx N.V. |
Stable formulations of polypeptides and uses thereof
|
|
MX2011010681A
(es)
|
2009-04-10 |
2012-01-20 |
Ablynx Nv |
Secuencias mejoradas de aminoacidos dirigidas contra il-6r y polipeptidos que comprenden el mismo para el tratamiento de enfermedades y trastornos relacionados con il-6r.
|
|
CA2759370C
(en)
|
2009-04-30 |
2020-02-11 |
Peter Schotte |
Method for the production of domain antibodies
|
|
WO2010142534A1
(en)
*
|
2009-05-27 |
2010-12-16 |
Ablynx Nv |
Biparatopic protein constructs directed against il-23
|
|
CN102459332B
(zh)
|
2009-06-05 |
2015-08-19 |
埃博灵克斯股份有限公司 |
用于预防和/或治疗呼吸道感染的单价、二价和三价抗人呼吸道合胞病毒(hrsv)纳米抗体构建体
|
|
ES2804450T3
(es)
|
2009-07-10 |
2021-02-08 |
Ablynx Nv |
Método para la producción de dominios variables
|
|
EP2473528B1
(en)
|
2009-09-03 |
2014-12-03 |
Ablynx N.V. |
Stable formulations of polypeptides and uses thereof
|
|
EP2486056A1
(en)
|
2009-10-09 |
2012-08-15 |
Ablynx N.V. |
Immunoglobulin single variable domain directed against human cxcr4 and other cell associated proteins and methods to generate them
|
|
JO3244B1
(ar)
|
2009-10-26 |
2018-03-08 |
Amgen Inc |
بروتينات ربط مستضادات il – 23 البشرية
|
|
WO2011064382A1
(en)
|
2009-11-30 |
2011-06-03 |
Ablynx N.V. |
Improved amino acid sequences directed against human respiratory syncytial virus (hrsv) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections
|
|
HRP20251657T1
(hr)
|
2009-12-14 |
2026-02-13 |
Ablynx N.V. |
Imunoglobulinska protutijela s jednostrukom varijabilnom domenom protiv ox40l, konstrukti i njihova terapijska upotreba
|
|
WO2011083140A1
(en)
|
2010-01-08 |
2011-07-14 |
Ablynx Nv |
Immunoglobulin single variable domain directed against human cxcr4
|
|
GB201000467D0
(en)
*
|
2010-01-12 |
2010-02-24 |
Ucb Pharma Sa |
Antibodies
|
|
SI2533761T1
(sl)
|
2010-02-11 |
2019-08-30 |
Ablynx N.V. |
Postopki in sestavki za pripravo aerosolov
|
|
PH12012501744A1
(en)
*
|
2010-03-03 |
2021-08-09 |
Boehringer Ingelheim Int |
Biparatopic abeta binding polypeptides
|
|
AU2011247612A1
(en)
|
2010-04-30 |
2012-12-06 |
Ablynx Nv |
Amino acid sequences of nanobodies directed against p19 subunit of the heterodimeric cytokine IL-23
|
|
US9932403B2
(en)
|
2010-05-20 |
2018-04-03 |
Ablynx Nv |
Biological materials related to HER3
|
|
NZ604007A
(en)
|
2010-05-27 |
2015-03-27 |
Genmab As |
Monoclonal antibodies against her2 epitope
|
|
IL299365A
(en)
|
2010-05-27 |
2023-02-01 |
Genmab As |
Monoclonal antibodies against 2HER
|
|
WO2011161263A1
(en)
|
2010-06-25 |
2011-12-29 |
Ablynx Nv |
Pharmaceutical compositions for cutaneous administration
|
|
DE102010026061A1
(de)
|
2010-06-30 |
2012-01-05 |
Siemens Aktiengesellschaft |
11C-markiertes Peptid zur Detektion eines Tumors, der einen Her2/neu-Rezeptor exprimiert
|
|
AU2011277983C1
(en)
*
|
2010-07-16 |
2016-09-29 |
Ablynx Nv |
Modified single domain antigen binding molecules and uses thereof
|
|
US11644471B2
(en)
|
2010-09-30 |
2023-05-09 |
Ablynx N.V. |
Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
|
|
WO2012042026A1
(en)
|
2010-09-30 |
2012-04-05 |
Ablynx Nv |
Biological materials related to c-met
|
|
EP2632946B1
(en)
|
2010-10-29 |
2017-12-06 |
Ablynx N.V. |
Method for the production of immunoglobulin single variable domains
|
|
JP5736764B2
(ja)
*
|
2010-12-21 |
2015-06-17 |
Jnc株式会社 |
発光活性を有する融合蛋白質
|
|
EP2655413B1
(en)
|
2010-12-23 |
2019-01-16 |
F.Hoffmann-La Roche Ag |
Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
|
|
US9428565B2
(en)
|
2011-01-31 |
2016-08-30 |
The General Hospital Corporation |
Treatment and bioluminescent visualization using multimodal TRAIL molecules
|
|
WO2012130872A1
(en)
|
2011-03-28 |
2012-10-04 |
Ablynx Nv |
Method for producing solid formulations comprising immunoglobulin single variable domains
|
|
WO2012143524A2
(en)
|
2011-04-20 |
2012-10-26 |
Genmab A/S |
Bispecific antibodies against her2 and cd3
|
|
EP2699260B1
(en)
*
|
2011-04-20 |
2024-11-20 |
Genmab A/S |
Bispecifc antibodies against her2
|
|
UA117218C2
(uk)
|
2011-05-05 |
2018-07-10 |
Мерк Патент Гмбх |
Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
|
|
EP3590950A1
(en)
|
2011-05-09 |
2020-01-08 |
Ablynx NV |
Method for the production of immunoglobulin single varible domains
|
|
JP6400470B2
(ja)
*
|
2011-05-16 |
2018-10-03 |
ジェネロン(シャンハイ)コーポレイション リミテッド |
多重特異性Fab融合タンパク質および使用法
|
|
CA3141978A1
(en)
|
2011-06-23 |
2012-12-27 |
Ablynx Nv |
Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
|
|
EP3363813A1
(en)
|
2011-06-23 |
2018-08-22 |
Ablynx NV |
Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobin single variable domains
|
|
EP4350345A3
(en)
|
2011-06-23 |
2024-07-24 |
Ablynx N.V. |
Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobin single variable domains
|
|
AU2012273928A1
(en)
|
2011-06-23 |
2014-02-06 |
Ablynx Nv |
Immunoglobulin single variable domains directed against IgE
|
|
LT3466972T
(lt)
|
2011-06-23 |
2026-06-25 |
Ablynx Nv |
Serumo albuminą surišantys baltymai
|
|
MY167125A
(en)
*
|
2011-08-17 |
2018-08-13 |
Glaxo Group Ltd |
Modified proteins and peptides
|
|
US9346884B2
(en)
|
2011-09-30 |
2016-05-24 |
Ablynx N.V. |
Biological materials related to c-Met
|
|
CN106046161B
(zh)
|
2011-09-30 |
2019-09-13 |
埃博灵克斯股份有限公司 |
与C-Met相关的生物物质
|
|
CN102399288B
(zh)
*
|
2011-10-19 |
2013-06-05 |
山西德丰信成生物科技有限公司 |
针对免疫球蛋白Fc段的单域重链抗体
|
|
CN108424456B
(zh)
*
|
2011-11-23 |
2022-04-26 |
医学免疫有限责任公司 |
特异于her3的结合分子及其用途
|
|
EP2620772A1
(en)
*
|
2012-01-25 |
2013-07-31 |
APP Latvijas Biomedicinas petijumu un studiju centrs |
Gastric cancer biomarkers and methods of use thereof
|
|
US9862932B2
(en)
|
2012-07-24 |
2018-01-09 |
The General Hospital Corporation |
Oncolytic virus therapy for resistant tumors
|
|
EP2890720B1
(en)
*
|
2012-08-30 |
2019-07-17 |
The General Hospital Corporation |
Compositions and methods for treating cancer
|
|
EP2719706A1
(en)
|
2012-10-15 |
2014-04-16 |
Universität Zürich |
Bispecific HER2 ligands for cancer therapy
|
|
EP2906591A1
(en)
*
|
2012-10-15 |
2015-08-19 |
Universität Zürich |
Bispecific her2 ligands for cancer therapy
|
|
EP2738180A1
(en)
|
2012-11-30 |
2014-06-04 |
Molecular Partners AG |
Binding proteins comprising at least two binding domains against HER2.
|
|
WO2014087010A1
(en)
|
2012-12-07 |
2014-06-12 |
Ablynx N.V. |
IMPROVED POLYPEPTIDES DIRECTED AGAINST IgE
|
|
WO2014111550A1
(en)
*
|
2013-01-17 |
2014-07-24 |
Glaxosmithkline Intellectual Property Development Limited |
Modified anti-serum albumin binding proteins
|
|
CN111363047A
(zh)
|
2013-03-12 |
2020-07-03 |
分子模板公司 |
用于引起细胞内化的cd20结合免疫毒素及其使用方法
|
|
US10239951B2
(en)
*
|
2013-05-08 |
2019-03-26 |
Zymeworks Inc. |
Bispecific HER2 and HER3 antigen binding constructs
|
|
WO2015002985A2
(en)
*
|
2013-07-01 |
2015-01-08 |
University Of Maryland |
Fc coupled compositions and methods of their use
|
|
US20160251440A1
(en)
*
|
2013-09-26 |
2016-09-01 |
Ablynx N.V. |
Bispecific nanobodies
|
|
LT3074424T
(lt)
*
|
2013-11-27 |
2025-05-26 |
Zymeworks Bc Inc. |
Bispecifiniai antigeną surišantys konstruktai, nukreipti į her2
|
|
WO2015095412A1
(en)
*
|
2013-12-19 |
2015-06-25 |
Zhong Wang |
Bispecific antibody with two single-domain antigen-binding fragments
|
|
UA122479C2
(uk)
|
2014-01-24 |
2020-11-25 |
Дана-Фарбер Кенсер Інстітьют, Інк. |
Виділена молекула антитіла, яка зв’язується з людським білком програмованої смерті-1 (pd-1)
|
|
ES2749862T3
(es)
|
2014-01-27 |
2020-03-24 |
Molecular Templates Inc |
Polipéptidos efectores desinmunizados de subunidad A de toxina Shiga para aplicaciones en mamíferos
|
|
PL3099717T3
(pl)
|
2014-01-31 |
2019-10-31 |
Novartis Ag |
Cząsteczki przeciwciała dla TIM-3 i ich zastosowanie
|
|
ES2864124T3
(es)
|
2014-03-11 |
2021-10-13 |
Molecular Templates Inc |
Proteínas que comprenden regiones de unión, regiones efectoras de la subunidad A de toxina Shiga y motivos señal de localización de retículo endoplasmático carboxi terminal
|
|
PT3604333T
(pt)
|
2014-03-11 |
2021-06-07 |
Molecular Templates Inc |
Proteínas compreendendo regiões efetoras da subunidade a da toxina shiga próximas de amino-terminais e regiões de ligação do tipo imunoglobulina de direcionamento celular capazes de se ligarem especificamente a cd38
|
|
EA201691765A1
(ru)
|
2014-03-14 |
2016-12-30 |
Новартис Аг |
Молекулы антител против lag-3 и их применения
|
|
CN122399016A
(zh)
|
2014-03-15 |
2026-07-17 |
诺华股份有限公司 |
使用嵌合抗原受体治疗癌症
|
|
CA2943242A1
(en)
*
|
2014-03-21 |
2015-09-24 |
X-Body, Inc. |
Bi-specific antigen-binding polypeptides
|
|
WO2015160940A1
(en)
*
|
2014-04-15 |
2015-10-22 |
President And Fellows Of Harvard College |
Bi-specific agents
|
|
LT3248986T
(lt)
|
2014-05-16 |
2022-03-25 |
Ablynx Nv |
Imunoglobulino kintami domenai
|
|
IL318433A
(en)
|
2014-05-16 |
2025-03-01 |
Ablynx Nv |
Improved immunoglobulin variable complexes
|
|
US11009511B2
(en)
|
2014-05-16 |
2021-05-18 |
Ablynx N.V. |
Methods for detecting and/or measuring anti-drug antibodies, in particular treatment-emergent anti-drug antibodies
|
|
KR102496206B1
(ko)
|
2014-06-11 |
2023-02-06 |
몰레큘러 템플레이츠, 인코퍼레이션. |
프로테아제-절단 저항성의 시가 독소 a 서브유닛 작동체 폴리펩티드 및 이를 포함하는 세포-표적화 분자
|
|
NL2013661B1
(en)
|
2014-10-21 |
2016-10-05 |
Ablynx Nv |
KV1.3 Binding immunoglobulins.
|
|
GB201411320D0
(en)
|
2014-06-25 |
2014-08-06 |
Ucb Biopharma Sprl |
Antibody construct
|
|
JP6831777B2
(ja)
|
2014-07-21 |
2021-02-17 |
ノバルティス アーゲー |
Cd33キメラ抗原受容体を使用する癌の処置
|
|
AU2015292744C1
(en)
|
2014-07-21 |
2021-01-21 |
Novartis Ag |
Treatment of cancer using humanized anti-BCMA chimeric antigen receptor
|
|
JP2017528433A
(ja)
|
2014-07-21 |
2017-09-28 |
ノバルティス アーゲー |
低い免疫増強用量のmTOR阻害剤とCARの組み合わせ
|
|
WO2016014553A1
(en)
|
2014-07-21 |
2016-01-28 |
Novartis Ag |
Sortase synthesized chimeric antigen receptors
|
|
WO2016016329A1
(en)
|
2014-07-29 |
2016-02-04 |
Vrije Universiteit Brussel |
Radio-labelled antibody fragments for use in the prognosis, diagnosis of cancer as well as for the prediction of cancer therapy response
|
|
JP6289733B2
(ja)
*
|
2014-07-29 |
2018-03-07 |
フレイエ ユニヴェルシテイト ブリュッセルVrije Universiteit Brussel |
癌の予防及び/又は治療に用いるための放射標識抗体断片
|
|
WO2016019300A1
(en)
|
2014-07-31 |
2016-02-04 |
Novartis Ag |
Subset-optimized chimeric antigen receptor-containing t-cells
|
|
EP3180359A1
(en)
|
2014-08-14 |
2017-06-21 |
Novartis AG |
Treatment of cancer using gfr alpha-4 chimeric antigen receptor
|
|
EP3712171A1
(en)
|
2014-08-19 |
2020-09-23 |
Novartis AG |
Treatment of cancer using a cd123 chimeric antigen receptor
|
|
US10577417B2
(en)
|
2014-09-17 |
2020-03-03 |
Novartis Ag |
Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
|
|
SG11201702401RA
(en)
|
2014-10-14 |
2017-04-27 |
Novartis Ag |
Antibody molecules to pd-l1 and uses thereof
|
|
FI3223848T3
(fi)
|
2014-11-27 |
2025-02-28 |
Zymeworks Bc Inc |
Menetelmiä käyttää bispesifisiä antigeenia sitovia rakenteita, jotka kohdistuvat her2:een
|
|
US20180334490A1
(en)
|
2014-12-03 |
2018-11-22 |
Qilong H. Wu |
Methods for b cell preconditioning in car therapy
|
|
US11001625B2
(en)
|
2014-12-10 |
2021-05-11 |
Tufts University |
VHH based binding antibodies for anthrax and botulinum toxins and methods of making and using therefor
|
|
AU2015366284B2
(en)
|
2014-12-19 |
2021-07-22 |
Ablynx N.V. |
Cysteine linked nanobody dimers
|
|
AU2016239949A1
(en)
|
2015-03-31 |
2017-09-07 |
Sorriso Pharmaceuticals, Inc. |
Peptide construct having a protease-cleavable linker
|
|
EP3277719B1
(en)
|
2015-03-31 |
2022-03-16 |
Sorriso Pharmaceuticals, Inc. |
Polypeptides
|
|
WO2016156468A1
(en)
*
|
2015-03-31 |
2016-10-06 |
Vhsquared Limited |
Polypeptides
|
|
PL3280729T3
(pl)
|
2015-04-08 |
2022-08-22 |
Novartis Ag |
Terapie cd20, terapie cd22 i terapie skojarzone komórką eksprymującą chimeryczny receptor antygenowy (car) cd19
|
|
WO2016172583A1
(en)
|
2015-04-23 |
2016-10-27 |
Novartis Ag |
Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
|
|
HRP20191800T1
(hr)
|
2015-05-13 |
2019-12-27 |
Ablynx N.V. |
Polipeptidi koji regrutiraju t stanice koji se temelje na tcr alfa/beta reaktivnosti
|
|
ES2984656T3
(es)
|
2015-05-13 |
2024-10-30 |
Ablynx Nv |
Polipéptidos que reclutan linfocitos T en función de la reactividad a CD3
|
|
CA2984458A1
(en)
|
2015-05-13 |
2016-11-17 |
Zymeworks Inc. |
Antigen-binding constructs targeting her2
|
|
CN114656573B
(zh)
|
2015-05-30 |
2024-09-27 |
分子模板公司 |
去免疫化的志贺毒素a亚基支架和包含它们的细胞靶向分子
|
|
KR20250174696A
(ko)
*
|
2015-07-17 |
2025-12-12 |
브리제 유니버시타이트 브루셀 |
암 치료에 사용하기 위한 방사성 표지된 항체 단편
|
|
EP3325512B1
(en)
|
2015-07-23 |
2023-09-06 |
Inhibrx, Inc. |
Multivalent and multispecific gitr-binding fusion proteins
|
|
MX2018001208A
(es)
|
2015-07-26 |
2018-03-26 |
Molecular Templates Inc |
Moleculas con direccion a las celulas que comprenden efectores de la subunidad a de la toxina shiga y epitopos de celulas-t cd8+.
|
|
US20180340025A1
(en)
|
2015-07-29 |
2018-11-29 |
Novartis Ag |
Combination therapies comprising antibody molecules to lag-3
|
|
US20180207273A1
(en)
|
2015-07-29 |
2018-07-26 |
Novartis Ag |
Combination therapies comprising antibody molecules to tim-3
|
|
EP3328418A1
(en)
|
2015-07-29 |
2018-06-06 |
Novartis AG |
Combination therapies comprising antibody molecules to pd-1
|
|
CN105384825B
(zh)
|
2015-08-11 |
2018-06-01 |
南京传奇生物科技有限公司 |
一种基于单域抗体的双特异性嵌合抗原受体及其应用
|
|
CN105085656B
(zh)
*
|
2015-09-01 |
2018-04-27 |
中国人民解放军军事医学科学院基础医学研究所 |
P19/Ebi3复合物及其多克隆抗体在系统性红斑狼疮诊治中的应用
|
|
CR20180229A
(es)
|
2015-10-29 |
2018-08-24 |
Novartis Ag |
Conjugados de anticuerpos que comprenden un agonista del receptor tipo toll
|
|
AU2016347610A1
(en)
|
2015-10-30 |
2018-05-10 |
Ablynx Nv |
Polypeptides against IL-23
|
|
NO2768984T3
(cg-RX-API-DMAC7.html)
|
2015-11-12 |
2018-06-09 |
|
|
|
HUE057241T2
(hu)
|
2015-11-13 |
2022-04-28 |
Ablynx Nv |
Javított, szérumalbumint kötõ immunoglobulin variábilis domének
|
|
CN108473565B
(zh)
|
2015-11-18 |
2022-05-27 |
默沙东公司 |
Ctla4结合剂
|
|
AU2016357460B2
(en)
|
2015-11-18 |
2023-07-27 |
Ablynx Nv |
Improved serum albumin binders
|
|
US10544222B2
(en)
|
2015-11-18 |
2020-01-28 |
Merck Sharp & Dohme Corp. |
PD1/CTLA4 binders
|
|
IL300122A
(en)
|
2015-11-18 |
2023-03-01 |
Merck Sharp ַ& Dohme Llc |
Substances that bind to PD1 and/or LAG3
|
|
CN108495651A
(zh)
|
2015-12-17 |
2018-09-04 |
诺华股份有限公司 |
抗pd-1的抗体分子及其用途
|
|
CN108697794A
(zh)
|
2015-12-17 |
2018-10-23 |
诺华股份有限公司 |
C-met抑制剂和抗pd-1抗体分子的组合及其用途
|
|
PT3393504T
(pt)
|
2015-12-22 |
2025-12-30 |
Novartis Ag |
Recetor de antigénio quimérico (car) de mesotelina e anticorpo contra o inibidor de pd-l1 para utilização combinada em terapia anticancerígena
|
|
WO2017120213A1
(en)
*
|
2016-01-05 |
2017-07-13 |
Colorado State University Research Foundation |
Compositions comprising resurfaced cell-penetrating nanobodies and methods of use thereof
|
|
EP3851457A1
(en)
|
2016-01-21 |
2021-07-21 |
Novartis AG |
Multispecific molecules targeting cll-1
|
|
SG11201807489PA
(en)
|
2016-03-04 |
2018-09-27 |
Novartis Ag |
Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore
|
|
WO2017157305A1
(en)
|
2016-03-15 |
2017-09-21 |
Generon (Shanghai) Corporation Ltd. |
Multispecific fab fusion proteins and use thereof
|
|
EP3432924A1
(en)
|
2016-03-23 |
2019-01-30 |
Novartis AG |
Cell secreted minibodies and uses thereof
|
|
EP3436475A1
(en)
|
2016-03-29 |
2019-02-06 |
STCube & Co., Inc. |
Methods for selecting antibodies that specifically bind glycosylated immune checkpoint proteins
|
|
CN109195991B
(zh)
|
2016-03-29 |
2023-10-31 |
斯特库比股份有限公司 |
对糖基化pd-l1特异的双重功能抗体及其使用方法
|
|
US20230071283A1
(en)
|
2016-04-15 |
2023-03-09 |
Aimee S. Payne |
Compositions and methods for selective protein expression
|
|
WO2017210617A2
(en)
|
2016-06-02 |
2017-12-07 |
Porter, David, L. |
Therapeutic regimens for chimeric antigen receptor (car)- expressing cells
|
|
WO2017220645A1
(en)
|
2016-06-23 |
2017-12-28 |
Ablynx N.V. |
Improved pharmacokinetic assays for immunoglobulin single variable domains
|
|
EP3484455A2
(en)
|
2016-07-15 |
2019-05-22 |
Novartis AG |
Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor
|
|
US11746152B2
(en)
|
2016-07-20 |
2023-09-05 |
Stcube, Inc. |
Methods of cancer treatment and therapy using a combination of antibodies that bind glycosylated PD-L1
|
|
WO2018014260A1
(en)
|
2016-07-20 |
2018-01-25 |
Nanjing Legend Biotech Co., Ltd. |
Multispecific antigen binding proteins and methods of use thereof
|
|
KR20230100748A
(ko)
|
2016-07-28 |
2023-07-05 |
노파르티스 아게 |
키메라 항원 수용체 및 pd-1 억제제의 조합 요법
|
|
SG11201900885VA
(en)
|
2016-08-01 |
2019-02-27 |
Novartis Ag |
Treatment of cancer using a chimeric antigen receptor in combination with an inhibitor of a pro-m2 macrophage molecule
|
|
PL3896091T3
(pl)
|
2016-08-10 |
2024-04-29 |
Legend Biotech Ireland Limited |
Chimeryczne receptory antygenowe nakierowane na bcma i sposoby ich zastosowania
|
|
MY196882A
(en)
|
2016-09-22 |
2023-05-08 |
Molecular Partners Ag |
Recombinant binding proteins and their use
|
|
JP7467117B2
(ja)
|
2016-10-07 |
2024-04-15 |
ノバルティス アーゲー |
癌の治療のためのキメラ抗原受容体
|
|
WO2018068201A1
(en)
|
2016-10-11 |
2018-04-19 |
Nanjing Legend Biotech Co., Ltd. |
Single-domain antibodies and variants thereof against ctla-4
|
|
GB201618432D0
(en)
*
|
2016-11-01 |
2016-12-14 |
Matn Scient Ltd |
Detection and treatment of demyelinating diseases
|
|
US11840569B2
(en)
|
2016-11-16 |
2023-12-12 |
Ablynx N.V. |
T cell recruiting polypeptides capable of binding CD123 and TCR alpha/beta
|
|
WO2018104444A1
(en)
|
2016-12-07 |
2018-06-14 |
Ablynx Nv |
Improved serum albumin binding immunoglobulin single variable domains
|
|
EP4442709A3
(en)
|
2017-01-17 |
2024-12-25 |
Ablynx NV |
Improved serum albumin binders
|
|
EP3571224B1
(en)
|
2017-01-17 |
2024-08-07 |
Ablynx NV |
Improved serum albumin binders
|
|
US11535662B2
(en)
|
2017-01-26 |
2022-12-27 |
Novartis Ag |
CD28 compositions and methods for chimeric antigen receptor therapy
|
|
JP7186401B2
(ja)
*
|
2017-02-28 |
2022-12-09 |
フエー・イー・ベー・フエー・ゼツト・ウエー |
タンパク質の経口送達のための手段及び方法
|
|
WO2018160731A1
(en)
|
2017-02-28 |
2018-09-07 |
Novartis Ag |
Shp inhibitor compositions and uses for chimeric antigen receptor therapy
|
|
CN106866823A
(zh)
*
|
2017-03-08 |
2017-06-20 |
康众(北京)生物科技有限公司 |
一种抗Her2的纳米抗体
|
|
WO2018178307A1
(en)
|
2017-03-31 |
2018-10-04 |
Ablynx N.V. |
Improved immunogenicity assays
|
|
WO2018191188A1
(en)
*
|
2017-04-09 |
2018-10-18 |
Xiao Shouhua |
Biparatopic and multiparatopic antibodies with common light chain and method of use
|
|
MY200973A
(en)
|
2017-04-11 |
2024-01-26 |
Inhibrx Inc |
Multispecific Polypeptide Constructs Having Constrained Cd3 Binding And Methods Of Using The Same
|
|
EP3615055A1
(en)
|
2017-04-28 |
2020-03-04 |
Novartis AG |
Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
|
|
EP3615068A1
(en)
|
2017-04-28 |
2020-03-04 |
Novartis AG |
Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
|
|
AR111651A1
(es)
|
2017-04-28 |
2019-08-07 |
Novartis Ag |
Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación
|
|
CN109096396B
(zh)
*
|
2017-06-20 |
2022-01-04 |
华兰生物工程股份有限公司 |
一种抗pd-l1人源化纳米抗体及其应用
|
|
WO2018233624A1
(zh)
*
|
2017-06-20 |
2018-12-27 |
和迈生物科技有限公司 |
抗Her2纳米抗体及其编码序列和用途
|
|
MX2019015885A
(es)
|
2017-06-22 |
2020-09-10 |
Novartis Ag |
Moleculas de anticuerpo que se unen a cd73 y usos de las mismas.
|
|
CN111050791A
(zh)
|
2017-06-27 |
2020-04-21 |
诺华股份有限公司 |
用于抗tim-3抗体的给药方案及其用途
|
|
GB201710973D0
(en)
|
2017-07-07 |
2017-08-23 |
Avacta Life Sciences Ltd |
Scaffold proteins
|
|
SG10201913147WA
(en)
|
2017-07-11 |
2020-02-27 |
Compass Therapeutics Llc |
Agonist antibodies that bind human cd137 and uses thereof
|
|
WO2019018730A1
(en)
|
2017-07-20 |
2019-01-24 |
Novartis Ag |
DOSAGE REGIMES FOR ANTI-LAG3 ANTIBODIES AND USES THEREOF
|
|
US20210179709A1
(en)
|
2017-10-31 |
2021-06-17 |
Novartis Ag |
Anti-car compositions and methods
|
|
US11718679B2
(en)
|
2017-10-31 |
2023-08-08 |
Compass Therapeutics Llc |
CD137 antibodies and PD-1 antagonists and uses thereof
|
|
MX2020004756A
(es)
|
2017-11-16 |
2020-08-20 |
Novartis Ag |
Terapias de combinacion.
|
|
EP3713961A2
(en)
|
2017-11-20 |
2020-09-30 |
Compass Therapeutics LLC |
Cd137 antibodies and tumor antigen-targeting antibodies and uses thereof
|
|
SG11202004158QA
(en)
|
2017-12-28 |
2020-06-29 |
Nanjing Legend Biotech Co Ltd |
Single-domain antibodies and variants thereof against tigit
|
|
KR102845020B1
(ko)
|
2017-12-28 |
2025-08-12 |
난징 레전드 바이오테크 씨오., 엘티디. |
Pd-l1에 대한 항체 및 변이체
|
|
BR112020013244A2
(pt)
*
|
2018-01-04 |
2020-12-01 |
Shanghai Lumosa Therapeutics Co., Ltd. |
proteínas de fusão de anticorpo citosina-desaminase de domínio único
|
|
US12247060B2
(en)
|
2018-01-09 |
2025-03-11 |
Marengo Therapeutics, Inc. |
Calreticulin binding constructs and engineered T cells for the treatment of diseases
|
|
CA3084518A1
(en)
|
2018-01-15 |
2019-07-18 |
Nanjing Legend Biotech Co., Ltd. |
Single-domain antibodies and variants thereof against pd-1
|
|
AU2019215031C1
(en)
|
2018-01-31 |
2026-02-26 |
Novartis Ag |
Combination therapy using a chimeric antigen receptor
|
|
US20200392512A1
(en)
|
2018-02-26 |
2020-12-17 |
Ablynx N.V. |
Nucleotide sequences encoding peptide linkers
|
|
KR102954778B1
(ko)
|
2018-03-09 |
2026-04-20 |
발리터 인코포레이티드 |
관절 염증의 지속적인 관절내 치료를 위한 다가 펩티드 컨쥬게이트
|
|
MA51996A
(fr)
|
2018-03-13 |
2021-01-20 |
Smivet B V |
Anticorps à domaine unique se liant à la neurotoxine tétanique
|
|
EP3765517A1
(en)
|
2018-03-14 |
2021-01-20 |
Elstar Therapeutics, Inc. |
Multifunctional molecules that bind to calreticulin and uses thereof
|
|
CN120463807A
(zh)
|
2018-03-22 |
2025-08-12 |
表面肿瘤学有限责任公司 |
抗il-27抗体及其用途
|
|
AU2019241350B2
(en)
|
2018-03-30 |
2025-10-02 |
Nanjing Legend Biotech Co., Ltd. |
Single-domain antibodies against LAG-3 and uses thereof
|
|
JPWO2019198731A1
(ja)
*
|
2018-04-10 |
2021-04-22 |
国立大学法人東北大学 |
抗体断片及び該抗体断片を含む二重特異性抗体
|
|
TW202010757A
(zh)
|
2018-04-11 |
2020-03-16 |
美商英伊布里克斯公司 |
具有經受限cd3結合的多重特異性多肽構築體以及相關方法及用途
|
|
US20210147547A1
(en)
|
2018-04-13 |
2021-05-20 |
Novartis Ag |
Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof
|
|
KR20200143634A
(ko)
|
2018-04-17 |
2020-12-24 |
몰레큘러 템플레이츠, 인코퍼레이션. |
탈면역된 시가 독소 a 서브유닛 스캐폴드를 포함하는 her2-표적화 분자
|
|
US20210047405A1
(en)
|
2018-04-27 |
2021-02-18 |
Novartis Ag |
Car t cell therapies with enhanced efficacy
|
|
WO2019226658A1
(en)
|
2018-05-21 |
2019-11-28 |
Compass Therapeutics Llc |
Multispecific antigen-binding compositions and methods of use
|
|
CN112384534A
(zh)
|
2018-05-21 |
2021-02-19 |
指南针制药有限责任公司 |
用于增强nk细胞对靶细胞的杀死的组合物和方法
|
|
US20210213063A1
(en)
|
2018-05-25 |
2021-07-15 |
Novartis Ag |
Combination therapy with chimeric antigen receptor (car) therapies
|
|
WO2019232244A2
(en)
|
2018-05-31 |
2019-12-05 |
Novartis Ag |
Antibody molecules to cd73 and uses thereof
|
|
IL279367B2
(en)
|
2018-06-13 |
2026-05-01 |
Novartis Ag |
BCMA chimeric antigen receptors and their uses
|
|
CA3104295A1
(en)
|
2018-06-19 |
2019-12-26 |
Atarga, Llc |
Antibody molecules to complement component 5 and uses thereof
|
|
WO2020010250A2
(en)
|
2018-07-03 |
2020-01-09 |
Elstar Therapeutics, Inc. |
Anti-tcr antibody molecules and uses thereof
|
|
AR116109A1
(es)
|
2018-07-10 |
2021-03-31 |
Novartis Ag |
Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
|
|
JP2021531306A
(ja)
|
2018-07-25 |
2021-11-18 |
アドバンスド アクセラレーター アプリケーションズ エスエー |
神経内分泌腫瘍の処置の方法
|
|
EP3847196A4
(en)
|
2018-09-07 |
2023-01-04 |
ITabMed (HK) Limited |
BISPECIFIC ANTIGEN BINDING PROTEINS AND USES THEREOF
|
|
WO2020052543A1
(en)
|
2018-09-10 |
2020-03-19 |
Nanjing Legend Biotech Co., Ltd. |
Single-domain antibodies against cd33 and constructs thereof
|
|
KR20210075080A
(ko)
|
2018-10-08 |
2021-06-22 |
유니베르시태트 취리히 |
Her2-결합 사량체 폴리펩티드
|
|
JP7497351B2
(ja)
|
2018-11-13 |
2024-06-10 |
コンパス セラピューティクス リミテッド ライアビリティ カンパニー |
チェックポイント分子に対する多重特異性結合性構築物およびその使用
|
|
AU2019402189B2
(en)
|
2018-12-20 |
2023-04-13 |
Novartis Ag |
Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
|
|
US20210386763A1
(en)
|
2018-12-20 |
2021-12-16 |
Novartis Ag |
Pharmaceutical combinations
|
|
WO2020132810A1
(en)
|
2018-12-24 |
2020-07-02 |
Generon (Shanghai) Corporation Ltd. |
Multispecific antigen binding proteins capable of binding cd19 and cd3, and use thereof
|
|
EP3924054B1
(en)
|
2019-02-15 |
2025-04-02 |
Novartis AG |
3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
|
CA3123519A1
(en)
|
2019-02-15 |
2020-08-20 |
Novartis Ag |
Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
|
US10871640B2
(en)
|
2019-02-15 |
2020-12-22 |
Perkinelmer Cellular Technologies Germany Gmbh |
Methods and systems for automated imaging of three-dimensional objects
|
|
AU2020226893B2
(en)
|
2019-02-21 |
2025-02-27 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to T cell related cancer cells and uses thereof
|
|
JP7579795B2
(ja)
|
2019-02-21 |
2024-11-08 |
マレンゴ・セラピューティクス,インコーポレーテッド |
NKp30に結合する抗体分子およびその使用
|
|
EP3927371A1
(en)
|
2019-02-22 |
2021-12-29 |
Novartis AG |
Combination therapies of egfrviii chimeric antigen receptors and pd-1 inhibitors
|
|
JP7308477B2
(ja)
*
|
2019-03-11 |
2023-07-14 |
パナソニックIpマネジメント株式会社 |
抗体、複合体、それを用いた検出装置及び検出方法
|
|
PH12021552414A1
(en)
|
2019-03-29 |
2022-07-25 |
Atarga Llc |
Anti fgf23 antibody
|
|
RU2754760C2
(ru)
|
2019-04-02 |
2021-09-07 |
Закрытое Акционерное Общество "Биокад" |
Водная фармацевтическая композиция анти-il17a антитела и ее применение
|
|
CN111848805B
(zh)
*
|
2019-04-30 |
2023-05-05 |
非同(成都)生物科技有限公司 |
用于肿瘤免疫治疗的具有双Her2位点的双特异性抗体
|
|
JP7692844B2
(ja)
|
2019-06-21 |
2025-06-16 |
ソリッソ ファーマシューティカルズ,インク. |
ポリペプチド
|
|
CA3144566A1
(en)
|
2019-06-21 |
2020-12-24 |
Sorriso Pharmaceuticals, Inc. |
Polypeptides
|
|
US12570736B2
(en)
|
2019-06-21 |
2026-03-10 |
Sorriso Pharmaceuticals, Inc. |
Compositions
|
|
CN110499259B
(zh)
*
|
2019-07-22 |
2021-07-27 |
浙江工业大学 |
一种解酯耶氏酵母yw100-1及其应用
|
|
EP4021511A4
(en)
|
2019-08-28 |
2023-10-04 |
Starpharma Pty Ltd |
TARGETED DENDRIMER CONJUGATES
|
|
WO2021074695A1
(en)
|
2019-10-16 |
2021-04-22 |
Avacta Life Sciences Limited |
PD-L1 INHIBITOR - TGFβ INHIBITOR BISPECIFIC DRUG MOIETIES.
|
|
WO2021079195A1
(en)
|
2019-10-21 |
2021-04-29 |
Novartis Ag |
Tim-3 inhibitors and uses thereof
|
|
CN114786679A
(zh)
|
2019-10-21 |
2022-07-22 |
诺华股份有限公司 |
具有维奈托克和tim-3抑制剂的组合疗法
|
|
WO2021108661A2
(en)
|
2019-11-26 |
2021-06-03 |
Novartis Ag |
Chimeric antigen receptors and uses thereof
|
|
US20230057071A1
(en)
|
2019-12-20 |
2023-02-23 |
Novartis Ag |
Combination of anti tim-3 antibody mbg453 and anti tgf-beta antibody nis793, with or without decitabine or the anti pd-1 antibody spartalizumab, for treating myelofibrosis and myelodysplastic syndrome
|
|
EP3842452A1
(en)
|
2019-12-26 |
2021-06-30 |
Universitat Autònoma de Barcelona |
Scaffold proteins and therapeutic nanoconjugates based on nidogen
|
|
WO2021138474A2
(en)
|
2020-01-03 |
2021-07-08 |
Marengo Therapeutics, Inc. |
Anti-tcr antibody molecules and uses thereof
|
|
EP4090335A1
(en)
|
2020-01-17 |
2022-11-23 |
Novartis AG |
Combination comprising a tim-3 inhibitor and a hypomethylating agent for use in treating myelodysplastic syndrome or chronic myelomonocytic leukemia
|
|
CN115298322A
(zh)
|
2020-01-17 |
2022-11-04 |
贝克顿迪金森公司 |
用于单细胞分泌组学的方法和组合物
|
|
JP7481856B2
(ja)
|
2020-02-25 |
2024-05-13 |
シスメックス株式会社 |
改変抗体及びその製造方法、並びに抗体の熱安定性を向上させる方法
|
|
IL295878A
(en)
|
2020-02-27 |
2022-10-01 |
Novartis Ag |
Methods for producing cells expressing a chimeric antigen receptor
|
|
JP7512413B2
(ja)
*
|
2020-03-31 |
2024-07-08 |
ビオテウス・インコーポレイテッド |
抗pd-l1およびpd-l2抗体ならびにその誘導体および用途
|
|
US12080426B2
(en)
*
|
2020-04-06 |
2024-09-03 |
University Of Florida Research Foundation, Incorporated |
Functional deep neural network for high-dimensional data analysis
|
|
AU2021284918A1
(en)
*
|
2020-06-03 |
2023-01-05 |
Starpharma Pty Ltd |
Therapeutic conjugates
|
|
GB202101299D0
(en)
|
2020-06-09 |
2021-03-17 |
Avacta Life Sciences Ltd |
Diagnostic polypetides and methods
|
|
EP4168007A1
(en)
|
2020-06-23 |
2023-04-26 |
Novartis AG |
Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
|
|
CA3183887A1
(en)
|
2020-06-24 |
2021-12-30 |
Ruben POSTEL |
Combination comprising an adc or an aoc comprising a vhh, and a saponin or a ligand-saponin conjugate
|
|
JP7652807B2
(ja)
|
2020-06-24 |
2025-03-27 |
サプリーム テクノロジーズ,ベー.フェー. |
単一ドメイン抗体、サポニン及びエフェクター分子のコンジュゲート、それを含む医薬組成物、前記医薬組成物の治療的使用
|
|
EP4117730A1
(en)
|
2020-06-24 |
2023-01-18 |
Sapreme Technologies B.V. |
Conjugate of saponin and single-domain antibody, pharmaceutical composition comprising said conjugate, therapeutic use thereof
|
|
WO2021259507A1
(en)
|
2020-06-24 |
2021-12-30 |
Sapreme Technologies B.V. |
Conjugate of a single domain antibody, a saponin and an effector molecule, pharmaceutical composition comprising the same, therapeutic use of said pharmaceutical composition
|
|
WO2022006219A2
(en)
|
2020-07-02 |
2022-01-06 |
Trustees Of Tufts College |
Vhh polypeptides that bind to clostridium difficile toxin b and methods of use thereof
|
|
KR102486958B1
(ko)
*
|
2020-07-08 |
2023-01-11 |
한국과학기술원 |
인간 상피세포 증식인자 수용체 2형의 도메인 4에 특이적으로 결합하는 신규 폴리펩티드 및 이의 용도
|
|
CA3176556A1
(en)
|
2020-07-16 |
2022-01-20 |
Novartis Ag |
Anti-betacellulin antibodies, fragments thereof, and multi-specific binding molecules
|
|
WO2022026592A2
(en)
|
2020-07-28 |
2022-02-03 |
Celltas Bio, Inc. |
Antibody molecules to coronavirus and uses thereof
|
|
EP4188549A1
(en)
|
2020-08-03 |
2023-06-07 |
Novartis AG |
Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
|
WO2022031884A2
(en)
|
2020-08-05 |
2022-02-10 |
Synthekine, Inc. |
Il2rg binding molecules and methods of use
|
|
JP7743500B2
(ja)
|
2020-08-05 |
2025-09-24 |
シンセカイン インコーポレイテッド |
Il10受容体結合性分子および使用方法
|
|
CN116723859A
(zh)
*
|
2020-08-05 |
2023-09-08 |
辛德凯因股份有限公司 |
IL27Rα结合分子及使用方法
|
|
US12122839B2
(en)
|
2020-08-05 |
2024-10-22 |
Synthekine, Inc. |
IFNGR binding synthetic cytokines and methods of use
|
|
WO2022031929A1
(en)
|
2020-08-05 |
2022-02-10 |
Synthekine, Inc. |
Il12rb1-binding molecules and methods of use
|
|
WO2022032042A1
(en)
|
2020-08-05 |
2022-02-10 |
Synthekine, Inc. |
Il12 receptor synthetic cytokines and methods of use
|
|
MX2023001491A
(es)
|
2020-08-05 |
2023-03-08 |
Synthekine Inc |
Moleculas de union a gp130 y metodos de uso.
|
|
EP4192489A4
(en)
|
2020-08-05 |
2024-12-11 |
Synthekine, Inc. |
IL2RB-BINDING MOLECULES AND METHODS OF USE
|
|
US12540188B2
(en)
|
2020-08-05 |
2026-02-03 |
Synthekine, Inc. |
IL10Rα/IL2Rγ synthetic cytokines
|
|
WO2022032023A2
(en)
|
2020-08-05 |
2022-02-10 |
Synthekine, Inc. |
Il23r binding molecules and methods of use
|
|
WO2022031885A2
(en)
|
2020-08-05 |
2022-02-10 |
Synthekine, Inc. |
Il10ra binding molecules and methods of use
|
|
WO2022031942A2
(en)
|
2020-08-05 |
2022-02-10 |
Synthekine, Inc. |
Il12rb2 binding molecules and methods of use
|
|
WO2022031890A1
(en)
|
2020-08-05 |
2022-02-10 |
Synthekine, Inc. |
Ifngr2 binding molecules and methods of use
|
|
EP4192502A4
(en)
*
|
2020-08-05 |
2024-10-09 |
Synthekine, Inc. |
Compositions and methods related to il27 receptor binding
|
|
WO2022032005A2
(en)
|
2020-08-05 |
2022-02-10 |
Synthekine, Inc. |
Il10rb binding molecules and methods of use
|
|
US20230279126A1
(en)
*
|
2020-08-05 |
2023-09-07 |
Synthekine, Inc. |
Il23 receptor synthetic cytokines and methods of use
|
|
KR20230061392A
(ko)
*
|
2020-08-05 |
2023-05-08 |
신테카인, 인크. |
수용체 쌍형성과 관련된 조성물 및 방법
|
|
KR102846963B1
(ko)
*
|
2020-08-05 |
2025-08-18 |
신테카인, 인크. |
IL27Rα 결합 분자 및 사용 방법
|
|
WO2022043558A1
(en)
|
2020-08-31 |
2022-03-03 |
Advanced Accelerator Applications International Sa |
Method of treating psma-expressing cancers
|
|
US20230321285A1
(en)
|
2020-08-31 |
2023-10-12 |
Advanced Accelerator Applications International Sa |
Method of treating psma-expressing cancers
|
|
WO2022098771A1
(en)
*
|
2020-11-03 |
2022-05-12 |
Ab Studio Inc. |
Multispecific antibodies and uses thereof
|
|
WO2022097065A2
(en)
|
2020-11-06 |
2022-05-12 |
Novartis Ag |
ANTIBODY Fc VARIANTS
|
|
KR20230107617A
(ko)
|
2020-11-13 |
2023-07-17 |
노파르티스 아게 |
키메라 항원 수용체(car)-발현 세포를 사용한 병용 요법
|
|
CN116829587A
(zh)
*
|
2020-12-18 |
2023-09-29 |
先声再明医药有限公司 |
Her2抗体及其应用
|
|
WO2022129637A1
(en)
|
2020-12-18 |
2022-06-23 |
Ablynx Nv |
T cell recruiting polypeptides based on tcr alpha/beta reactivity
|
|
EP4284510A1
(en)
|
2021-01-29 |
2023-12-06 |
Novartis AG |
Dosage regimes for anti-cd73 and anti-entpd2 antibodies and uses thereof
|
|
BR112023016706A2
(pt)
|
2021-02-19 |
2023-10-31 |
Seoul Nat Univ R&Db Foundation |
Anticorpo ou um fragmento de ligação ao antígeno do mesmo, molécula de ácido nucleico, métodos para produzir um anticorpo ou um fragmento de ligação ao antígeno do mesmo e para detectar agrupamento de diferenciação 47 ou determinar uma quantidade de agrupamento de diferenciação 47 em uma amostra, e, uso do anticorpo ou de um fragmento de ligação ao antígeno do mesmo
|
|
BR112023016713A2
(pt)
|
2021-02-19 |
2023-10-31 |
Seoul Nat Univ R&Db Foundation |
Anticorpo ou um fragmento de ligação ao antígeno do mesmo, molécula de ácido nucleico, métodos para produzir um anticorpo ou um fragmento de ligação ao antígeno do mesmo e para detectar agrupamento de diferenciação 47 ou determinar uma quantidade de agrupamento de diferenciação 47 em uma amostra, e, uso do anticorpo ou de um fragmento de ligação ao antígeno do mesmo
|
|
TW202304979A
(zh)
|
2021-04-07 |
2023-02-01 |
瑞士商諾華公司 |
抗TGFβ抗體及其他治療劑用於治療增殖性疾病之用途
|
|
WO2022234003A1
(en)
|
2021-05-07 |
2022-11-10 |
Avacta Life Sciences Limited |
Cd33 binding polypeptides with stefin a protein
|
|
AR125874A1
(es)
|
2021-05-18 |
2023-08-23 |
Novartis Ag |
Terapias de combinación
|
|
AU2022301099A1
(en)
*
|
2021-07-01 |
2024-02-15 |
Ningbo T-Maximum Biopharmaceuticals Co., Ltd. |
Antigen-binding polypeptide targeting b7h3 and application thereof
|
|
EP4512826A3
(en)
|
2021-07-09 |
2025-04-02 |
Luxembourg Institute Of Health (LIH) |
Dimeric protein complexes and uses thereof
|
|
AU2022314734A1
(en)
|
2021-07-19 |
2024-02-08 |
Regeneron Pharmaceuticals, Inc. |
Il12 receptor agonists and methods of use thereof
|
|
IL311003A
(en)
*
|
2021-08-25 |
2024-04-01 |
Denali Therapeutics Inc |
Anti-2HER antibodies and methods of using them
|
|
US20240392035A1
(en)
*
|
2021-08-25 |
2024-11-28 |
Denali Therapeutics Inc. |
Engineered anti-her2 bispecific proteins
|
|
US11970548B2
(en)
*
|
2021-08-27 |
2024-04-30 |
Innovative Cellular Therapeutics Holdings, Ltd. |
Nanobody target GCC and uses in chimeric antigen receptor cell therapy
|
|
CN113813380B
(zh)
*
|
2021-09-15 |
2023-03-07 |
深圳大学 |
一种靶向her2的光热纳米材料及其制备方法与应用
|
|
WO2023044483A2
(en)
|
2021-09-20 |
2023-03-23 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of her2 positive cancer
|
|
WO2023057946A1
(en)
|
2021-10-07 |
2023-04-13 |
Avacta Life Sciences Limited |
Serum half-life extended pd-l1 binding polypeptides
|
|
TW202334196A
(zh)
|
2021-10-07 |
2023-09-01 |
英商阿法克塔生命科學有限公司 |
Pd-l1結合多肽
|
|
WO2023070317A1
(zh)
*
|
2021-10-26 |
2023-05-04 |
江苏省农业科学院 |
基于dc细胞的双功能纳米抗体及其构建方法和应用
|
|
WO2023092004A1
(en)
|
2021-11-17 |
2023-05-25 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of tau-related disorders
|
|
WO2023121447A1
(en)
|
2021-12-22 |
2023-06-29 |
Sapreme Technologies B.V. |
Conjugate of a single domain antibody, a saponin and an effector molecule, pharmaceutical composition comprising the same, therapeutic use of said pharmaceutical composition
|
|
TW202342548A
(zh)
|
2022-02-07 |
2023-11-01 |
美商威特拉公司 |
抗獨特型(anti-idiotype)抗體分子及其用途
|
|
WO2023153876A1
(ko)
|
2022-02-10 |
2023-08-17 |
주식회사 아피셀테라퓨틱스 |
Cd40l에 특이적으로 결합하는 스테핀 a 단백질 변이체 및 이의 용도
|
|
US20250270318A1
(en)
*
|
2022-03-21 |
2025-08-28 |
Ab Therapeutics, Inc. |
Multispecific antibodies and uses thereof
|
|
EP4504796A4
(en)
*
|
2022-04-04 |
2026-03-18 |
Nat Inst Biotechnology Negev Ltd |
SPECIFIC BINDING MOLECULES OF THE HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2
|
|
CA3255622A1
(en)
*
|
2022-04-15 |
2023-10-19 |
Valitor, Inc. |
HUMANIZED MULTIVALENT PROTEIN CONJUGATES
|
|
CN114805578B
(zh)
*
|
2022-05-06 |
2022-12-06 |
浙江大学 |
一种白细胞免疫球蛋白样受体亚家族b成员2的羊驼纳米抗体、制备方法及其应用
|
|
WO2023218243A1
(en)
|
2022-05-12 |
2023-11-16 |
Avacta Life Sciences Limited |
Lag-3/pd-l1 binding fusion proteins
|
|
WO2023220695A2
(en)
|
2022-05-13 |
2023-11-16 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of her2 positive cancer
|
|
AU2023276697A1
(en)
*
|
2022-05-23 |
2024-12-12 |
Cereius, Inc. |
Her2-binding agents and uses thereof
|
|
AU2023313033A1
(en)
|
2022-07-27 |
2025-03-13 |
Ablynx Nv |
Polypeptides binding to a specific epitope of the neonatal fc receptor
|
|
CA3263767A1
(en)
|
2022-08-03 |
2024-02-08 |
Voyager Therapeutics, Inc. |
COMPOSITIONS AND PROCESSES ALLOWING CROSSING THE BLOOD-BRAIN BARRIER
|
|
WO2024094165A1
(zh)
*
|
2022-11-04 |
2024-05-10 |
茂行制药(苏州)有限公司 |
靶向b7h3的通用型car-t细胞及其制备方法和应用
|
|
WO2024129897A2
(en)
*
|
2022-12-13 |
2024-06-20 |
Bj Bioscience Inc. |
Anti-cd3 antibodies and bispecific antibodies
|
|
US12195546B2
(en)
|
2022-12-19 |
2025-01-14 |
Sanofi |
CD28/OX40 bispecific antibodies
|
|
US20240415974A1
(en)
|
2022-12-23 |
2024-12-19 |
Ablynx N.V. |
Protein-based conjugation carriers
|
|
AU2024207005A1
(en)
|
2023-01-13 |
2025-08-28 |
Regeneron Pharmaceuticals, Inc. |
Il12 receptor agonists and methods of use thereof
|
|
WO2024168061A2
(en)
|
2023-02-07 |
2024-08-15 |
Ayan Therapeutics Inc. |
Antibody molecules binding to sars-cov-2
|
|
IL322519A
(en)
|
2023-02-17 |
2025-10-01 |
Ablynx Nv |
Polypeptides that bind to the neonatal fc receptor
|
|
WO2024200987A1
(en)
|
2023-03-31 |
2024-10-03 |
Avacta Life Sciences Limited |
Tnfr2 binding polypeptides and methods of use
|
|
FR3147278A1
(fr)
|
2023-03-31 |
2024-10-04 |
Avacta Life Sciences Limited |
Polypeptides de liaison au tnfr2 et procedes d'utilisation
|
|
CN121398855A
(zh)
|
2023-04-24 |
2026-01-23 |
默沙东有限责任公司 |
Trop2结合剂及其缀合物
|
|
WO2024259305A1
(en)
|
2023-06-14 |
2024-12-19 |
The Broad Institute, Inc. |
Vhh polypeptides that bind to mesothelin, compositions and methods of use thereof
|
|
CN122122303A
(zh)
|
2023-06-22 |
2026-05-29 |
阿布林克斯有限公司 |
用于调节细胞因子受体活性的嵌合蛋白
|
|
US20250034260A1
(en)
|
2023-07-05 |
2025-01-30 |
Sanofi |
Fcrn antagonists for treatment of igg-related diseases and disorders
|
|
CN116574186B
(zh)
*
|
2023-07-07 |
2023-11-28 |
云南大学 |
特异性结合her2的纳米抗体及其应用
|
|
WO2025034806A1
(en)
|
2023-08-08 |
2025-02-13 |
Wisconsin Alumni Research Foundation |
Single-domain antibodies and variants thereof against fibroblast activation protein
|
|
WO2025038362A1
(en)
|
2023-08-11 |
2025-02-20 |
Merck Sharp & Dohme Llc |
Monovalent interleukin 12 (il-12) heterodimeric fc proteins
|
|
WO2025061919A1
(en)
|
2023-09-22 |
2025-03-27 |
Ablynx Nv |
Bi- and multivalent albumin binders
|
|
IL328245A
(en)
|
2023-11-08 |
2026-07-01 |
Sanofi Sa |
CD25-based lysosomal compartment and its uses
|
|
WO2025122634A1
(en)
|
2023-12-05 |
2025-06-12 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of tau-related disorders
|
|
WO2025175359A1
(en)
*
|
2024-02-23 |
2025-08-28 |
HAFENSTEIN, Patrick |
Immunoconjugate, pharmaceutical composition comprising the same, and uses thereof in treating cancers
|
|
GB202403780D0
(en)
|
2024-03-15 |
2024-05-01 |
Avacta Life Sciences Ltd |
Polypeptides and methods for detecting and quantifying small molecules
|
|
TW202602933A
(zh)
|
2024-03-28 |
2026-01-16 |
美商健臻公司 |
與轉鐵蛋白受體1的特異性表位結合的多肽
|
|
WO2025262150A2
(en)
|
2024-06-18 |
2025-12-26 |
Ablynx Nv |
Antibody-recruiting molecules
|
|
WO2026036047A1
(en)
|
2024-08-08 |
2026-02-12 |
Altus Enterprises, Inc. |
Antibody molecules to fixa and fx and uses thereof
|
|
WO2026052756A1
(en)
|
2024-09-05 |
2026-03-12 |
Ablynx Nv |
Her2 binding immunoglobulin single variable domains, constructs comprising the same and uses thereof
|
|
US20260167709A1
(en)
|
2024-09-11 |
2026-06-18 |
Novartis Ag |
Antibodies targeting il-31
|
|
WO2026076388A1
(en)
|
2024-10-03 |
2026-04-09 |
The Broad Institute, Inc. |
Vhh polypeptides that bind to claudin-18, compositions and methods of use thereof
|
|
WO2026102093A1
(en)
|
2024-11-07 |
2026-05-15 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of tau-related disorders
|
|
WO2026122407A1
(en)
|
2024-12-04 |
2026-06-11 |
Merck Sharp & Dohme Llc |
Amyloid beta binder, and uses thereof
|
|
WO2026151679A1
(en)
|
2025-01-07 |
2026-07-16 |
Compass Therapeutics, Llc. |
Multispecific binding constructs targeting pd-1 and vegf and uses thereof
|
|
WO2026156021A1
(en)
|
2025-01-16 |
2026-07-23 |
Merck Sharp & Dohme Llc |
Bispecific antibody constructs that bind alpp/alppl2 and cd3
|